Introduction
Genetic factors and/or exposure to environmental factors may contribute to the occurrence of human cancers. Risk factors for gastric cancer have been shown to include polymorphisms of nitroso compound activating enzyme [1, 2] , and the genetic polymorphisms [3] [4] [5] may be responsible for susceptibility to cancer as endogenous and/or host factors; as well, Helicobacter pylori infection [6] [7] [8] [9] [10] , excessive sodium chloride intake [11] , and Epstein-Barr (EB) virus infection [12] appear to play pivotal roles in the development of the cancer, as exogenous factors.
Reports [13] [14] [15] describing the occurrence of gastric cancer as being derived from the pathway of H. pyloriassociated atrophic gastritis have been published. Longterm infection with H. pylori has been reported to result in H. pylori-associated chronic atrophic gastritis, which has been shown to correlate closely with gastric cancer, especially in young adults [16] [17] [18] [19] . The endoscopic characteristics of H. pylori-associated gastritis in young adults have revealed nodular, rugal hyperplastic, and chronic atrophic gastritis to be specifi c to patients with H. pylori infection [20] .
Cytochrome P4502E1 (CYP2E1) activates carcinogenic N-nitrosamines and other potential human carcinogens. Genetic polymorphisms of CYP2E1 have been shown to confer individual susceptibility to human cancers. Esophago-gastrointestinal cancers have been reported to be relevant to the expression of CYP2E1 and to N-nitrosamine metabolism [21] [22] [23] . It would thus be worthwhile to investigate whether the frequency of CYP2E1 restriction fragment-length polymorphism (RFLP) differs among gastric cancer patients younger than 40 years, patients in their sixties, and those 80 years or older.
The present studies were therefore designed to clarify the risk factors for gastric cancer in young adults; Abstract Background. Gastric cancers in young adults are thought to be associated with risk factors that include Helicobacter pylori infection and genetic polymorphism. The objective of this study was to elucidate the roles of these risk factors in patients younger than 40 years by analyzing clinicopathological data and H. pylori infection, and using molecular epidemiologic techniques. Methods. Clinicopathological features, the presence of H. pylori infection, endoscopic characteristics of gastritis, genetic polymorphism of P4502E1 (CYP2E1), and family history of cancer in patients with gastric cancer treated surgically at Nippon Medical School Hospital from 1991 to 2004 were analyzed, based on our medical database. Results. Gastric cancer in those younger than 40 years was characterized by a predominance of female patients with poorly differentiated adenocarcinoma who had undergone total gastrectomy with extended lymphadenectomy. H. pylori infection had a higher prevalence in patients with gastric cancer than in patients with normal endoscopic results or chronic gastritis, especially in those younger than 40 years (odds ratio, 13.7). Atrophic gastritis, nodular gastritis, and rugal hyperplastic gastritis were observed by endoscopy as H. pyloriassociated gastritis. No difference in the incidence of either CYP2E1 genetic polymorphism or a family history of cancer was observed among different age groups. Conclusion. Gastric cancer in patients younger than 40 years is closely associated with H. pylori infection, but not with genetic characteristics. Eradication therapy for H. pylori and endoscopic examination of H. pylori-positive young adults may be anticipated to be adopted as a strategy for the prevention and/or early detection of cancer.
the clinicopathological features of gastric cancer, based on clinical and pathological records; the incidences of H. pylori infection and H. pylori-associated gastritis, detected by blood tests and endoscopic biopsy; the frequency of CYP2E1 genetic polymorphism; and family history. Based on the results, current trials aimed at the reduction of risk factors are briefl y discussed.
Patients and methods
A medical database containing retrospective documented variables in patients treated consecutively for gastric cancer at our hospital from 1991 to 2004 was analyzed. All patients had undergone gastrectomy with D0, D1, D2 or D3 type lymphadenectomy.
Clinicopathological studies
Clinicopathological fi ndings, classifi ed according to the Japanese Gastric Cancer Association Japanese classification of gastric carcinoma [24] and obtained from operative records and pathology reports, were fi led using the File Maker Pro system (FileMaker, Santa Clara, CA, USA). The gastric cancer cases were then divided into early and advanced types according to the depth of tumor invasion in the gastric wall.
Surgical techniques
Five faculty surgeons, all specialists in gastric surgery, performed the operations. The most appropriate surgical procedure (total, proximal, or distal gastrectomy) was selected based on location, tumor size, and the extent of nodal involvement. For stage I gastric cancer surgery, the degree of lymph node dissection was selected at the surgeon's discretion. D2 dissection was the standard method for stages II and III, and D3 dissection was selected for nonelderly patients with stage III gastric cancer.
Endoscopic diagnosis of gastric cancer and H. pyloriassociated gastritis
Endoscopic diagnosis was performed with gastrointestinal (GI) fi berscopes by a specialist in GI endoscopy. Retrospectively, the fi nal diagnosis of gastric cancer and H. pylori-associated gastritis was made independently, based on observation of the endoscopic fi lms by two GI endoscopy specialists. Any diagnostic discrepancy was discussed until agreement was reached. Criteria for endoscopic diagnosis were based on the Sydney system [25] , and nodular gastritis was diagnosed according to previous reports [26, 27] .
Enzyme-linked immunosorbent assay (ELISA) for serum IgG antibody to H. pylori in patients with gastric cancer, those with peptic ulcer, and those with chronic gastritis who were endoscopically normal
Blood samples were collected and stored at −80 °C until the assay. Serum IgG antibody to H. pylori was assayed by ELISA (AMRAD Operation, Australia), and absorbance at 450 nm was measured. The results were expressed quantitatively, with less than 30 U/ml regarded as a negative result.
Detection of H. pylori by endoscopic biopsy in patients with gastric cancer, those with peptic ulcer, and those with chronic gastritis who were endoscopically normal
Endoscopic biopsy specimens were collected from: (1) the greater curvature of the antrum; (2) the greater curvature of the upper corpus; and (3) the lesser curvature of the lower corpus, for the detection of H. pylori. Hematoxylin-and-eosin staining, improved toluidine blue staining, and H. pylori-specifi c-antibody immunostaining (DAKO, Glostrup, Denmark) were used for the histological detection of H. pylori organisms.
Restricted fragment-length polymorphism (RFLP) analysis of CYP2E1
DNA was isolated from peripheral blood buffy coats by phenol extraction methods, as previously described. The polymerase chain reaction (PCR) was used to amplify the transcription regulatory region of CYP2E1, which includes the restriction enzyme recognition site for RsaI. Genomic DNA (0.1 µg) was amplifi ed with primers (5′-TTCATTCTGTCTTCTAACTGG and 5′-TTCATTCTGTCTTCTAACTCG) according to previously reported methods [28] . The PCR product (15 µl) was subjected to RsaI restriction enzyme analysis by electrophoresis in an agarose gel (2.2%). The presence of the restriction site yielded two fragments, of 360 and 52 bp.
Family history
Family histories of the patients with gastric cancer were obtained by interviews conducted by attending doctors, who spoke to the patients themselves and/or their relatives; the presence of cancer in second-degree relatives was taken as a positive family history.
Statistical analysis
Statistical analysis was checked by the χ 2 test, and cumulative survival rates were calculated using the Kaplan-Meier method and Stat View software (SAS Institute, USA); survival curves were tested using the Logrank method. A P-value of less than 0.05 was considered signifi cant.
Informed consent
All patients were informed of their therapeutic options. No treatments were performed without informed consent.
Ethics
The study protocol conformed to the ethical guidelines established by the 1975 Declaration of Helsinki and was approved by the institutional review board of Nippon Medical School.
Results

Clinicopathological features of gastric cancer in patients younger than 40 years
Patients younger than 40 years were characterized by a prevalence of female patients, mid-stomach cancer location, and poorly differentiated adenocarcinoma histologically.
Incidence of H. pylori infection
The H. pylori infection results in 31 patients younger than 40 years were used in this study. The positive rate in this group was 71% in males, and 88% in females. The positive rates for H. pylori in patients with gastric cancer regardless of age (n = 362) ranged from 70% to 80%, and were unaffected by age. The positive rates in patients with normal endoscopic fi ndings and chronic gastritis (n = 721) were 23.3% in those younger than 40 years, 48.4% in patients in their forties, and 56.8%, 61.7%, 60.7%, and 55.6% in patients in their fi fties, sixties, seventies, and those 80 years or older, respectively. In the peptic ulcer group (n = 939), the positive rate was more than 70% in those in their thirties to sixties, but the prevalence declined after the seventies. The odds ratios for H. pylori infection in patients with gastric cancer and the patients with normal endoscopic fi ndings and chronic gastritis are shown in Table 1 , the highest odds ratio was 13.69, in patients younger than 40 years. Odds ratios were higher in patients with gastric cancer than in those with normal endoscopic fi ndings and chronic gastritis, regardless of age.
H. pylori-associated gastritis
Fifteen of the 31 (48.4%) patients aged less than 40 years were diagnosed as having atrophic gastritis in the gastric body; 3 of the 31 (9.7%) also had nodular gastritis in the antrum, and 1 of the 31 (3.2%) showed rugal hyperplastic gastritis in the gastric body.
RFLP analysis of CYP2E1
The results of the CYP2E1 polymorphism analysis in patients with gastric cancer are shown in Table 2 , stratifi ed by age group for those younger than 40 years, those in their sixties, and those 80 years or older. In the CYP2E1 RsaI restriction analysis, the homozygous minor genotype (R/R) and heterozygous genotype (C/ R) were not found to differ signifi cantly among the three groups. Table 2 also shows the prevalence of a family history of cancer, stratifi ed by the above three age groups. No signifi cant differences were observed among the three groups. 
Family history of cancer
Discussion
In 31 patients younger than 40 years with gastric cancer who underwent surgery between 1991 and 2004, the clinicopathological features, presence of H. pylori infection, and characteristics of gastritis were examined; CYP2E1 genetic polymorphism and family history were also investigated, in comparison with fi ndings in patients with gastric cancer in their sixties and 80 years or older. Clinicopathological features in the 31 patients younger than 40 years with gastric cancer were characterized by the predominance of female patients with poorly differentiated adenocarcinoma, located in the middle part of the stomach, many of whom had undergone total gastrectomy with D2 or D3 lymph node dissection. The predominance of female patients with poorly differentiated adenocarcinoma that we observed was in accordance with other reports [29, 30] .
As compared with the results in the patients with normal endoscopic fi ndings and chronic gastritis, the predominance of H. pylori infection in the patients younger than 40 was striking; 71% of the male and 88% of the female patients being positive for H. pylori. Gastric cancer in young adults has been found to be associated with H. pylori infection. An increasing number of reports have stressed the association of H. pylori infection with the development of gastric cancer in young adults [16] [17] [18] pylori-associated gastritis and the development of the diffuse type of cancer has been considered by Uemura et al. [14] , who noted that gastric mucosa with severe infl ammation and moderate atrophy induced by H. pylori infection had a potential risk for undifferentiated gastric cancer. Miyamoto et al. [26, 27] have reported that nodular gastritis which is induced by H. pylori infection is closely associated with gastric cancer in young adults. A bird-skin appearance in endoscopy and hyperplasia of B-lymphocytes are characteristics of nodular gastritis, which is considered to represent marked infl ammation. Active and chronic infl ammatory cellular infi ltrations were found to correlate with H. pylori in- [32] .
Other recent reports have suggested that CYP2E1 genetic polymorphism is responsible for susceptibility to GI cancers as well as lung cancer [21] [22] [23] . The present study yielded negative results regarding an association of CYP2E1 genetic polymorphism with the occurrence of gastric cancer in patients younger than 40 years. No association of CYP2E1 genetic polymorphism or other genetic factors with gastric cancer has been reported previously [28] .
Familial clustering of cancer in patients with gastric cancer was studied in the present investigation, but no difference in the prevalence of family history was found among the three age groups we examined. Familial aggregation was reported to be specifi c for the intestinal type of gastric cancer in a patient with a positive family history [33] . Intrafamilial clustering of H. pylori infection was reported to have a crucial role in familial aggregation of gastric cancer [34] .
In conclusion, a high prevalence of H. pylori infection in patients with gastric cancer younger than 40 years was confi rmed in the present study. Eradication therapy for H. pylori would therefore be expected to prevent gastric cancer development, as this cancer arises from H. pylori-associated gastritis. Furthermore, endoscopic GI examinations in people who are H. pylori-positive would promote the early detection of cancer. Trials of H. pylori eradication therapy for the prevention of gastric cancer are currently underway in China and Japan, and promising results are being obtained [35, 36] .
